Opis projektu
Rozwój terapii komórkowej z wykorzystaniem limfocytów T regulatorowych
Choroby związane z układem odpornościowym, takie jak choroby autoimmunologiczne i przewlekłe zapalenie, stanowią spore obciążenie społeczno-ekonomiczne. Leczenie tych chorób zazwyczaj opiera się na lekach immunosupresyjnych, a limfocyty T stanowią obiecujące podejście terapeutyczne. Zespół finansowanego przez UE projektu RESHAPE chce zbadać główną rolę, jaką limfocyty T regulatorowe odgrywają w homeostazie układu odpornościowego poprzez supresję nadmiernej odpowiedzi odpornościowej. Głównym celem jest opracowanie zaawansowanych terapii opartych na limfocytach T regulatorowych i wykazanie ich skuteczności w przywracaniu równowagi odpornościowej po klinicznym transferze adaptywnym u pacjentów z chorobami immunologicznymi.
Cel
Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy.
Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments.
Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation.
Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies
Dziedzina nauki
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Słowa kluczowe
Program(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSzczegółowe działanie
H2020-SC1-2018-Single-Stage-RTD
System finansowania
RIA - Research and Innovation actionKoordynator
10117 Berlin
Niemcy